- Home
- ARVN vs HQL Comparison
ARVN vs HQL Comparison
Compare ARVN & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- HQL
- Stock Information
- Founded
- ARVN 2015
- HQL 1992
- Country
- ARVN United States
- HQL United States
- Employees
- ARVN N/A
- HQL N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- HQL Investment Managers
- Sector
- ARVN Health Care
- HQL Finance
- Exchange
- ARVN Nasdaq
- HQL Nasdaq
- Market Cap
- ARVN 456.2M
- HQL 369.6M
- IPO Year
- ARVN 2018
- HQL N/A
- Fundamental
- Price
- ARVN $7.73
- HQL $12.94
- Analyst Decision
- ARVN Buy
- HQL
- Analyst Count
- ARVN 21
- HQL 0
- Target Price
- ARVN $20.53
- HQL N/A
- AVG Volume (30 Days)
- ARVN 2.1M
- HQL 120.9K
- Earning Date
- ARVN 07-29-2025
- HQL 01-01-0001
- Dividend Yield
- ARVN N/A
- HQL 11.56%
- EPS Growth
- ARVN N/A
- HQL N/A
- EPS
- ARVN N/A
- HQL 0.79
- Revenue
- ARVN $426,900,000.00
- HQL N/A
- Revenue This Year
- ARVN $4.26
- HQL N/A
- Revenue Next Year
- ARVN N/A
- HQL N/A
- P/E Ratio
- ARVN N/A
- HQL $17.08
- Revenue Growth
- ARVN 498.74
- HQL N/A
- 52 Week Low
- ARVN $5.90
- HQL $11.34
- 52 Week High
- ARVN $34.11
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- ARVN 50.16
- HQL 55.81
- Support Level
- ARVN $7.09
- HQL $12.34
- Resistance Level
- ARVN $7.89
- HQL $12.87
- Average True Range (ATR)
- ARVN 0.35
- HQL 0.19
- MACD
- ARVN 0.00
- HQL -0.00
- Stochastic Oscillator
- ARVN 38.14
- HQL 60.26
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.